1. Home
  2. CRMD vs PRTC Comparison

CRMD vs PRTC Comparison

Compare CRMD & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CorMedix Inc.

CRMD

CorMedix Inc.

HOLD

Current Price

$6.61

Market Cap

509.9M

Sector

Health Care

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

N/A

Current Price

$15.91

Market Cap

464.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CRMD
PRTC
Founded
2006
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
509.9M
464.3M
IPO Year
2009
N/A

Fundamental Metrics

Financial Performance
Metric
CRMD
PRTC
Price
$6.61
$15.91
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$14.67
N/A
AVG Volume (30 Days)
1.4M
3.8K
Earning Date
03-05-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
780.00
N/A
EPS
2.04
N/A
Revenue
$311,709,000.00
N/A
Revenue This Year
$0.30
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.17
$8.09
Revenue Growth
617.03
N/A
52 Week Low
$5.60
$13.30
52 Week High
$17.43
$20.00

Technical Indicators

Market Signals
Indicator
CRMD
PRTC
Relative Strength Index (RSI) 43.67 38.23
Support Level $6.55 $15.60
Resistance Level $7.44 $18.10
Average True Range (ATR) 0.24 0.48
MACD 0.05 -0.09
Stochastic Oscillator 58.83 9.13

Price Performance

Historical Comparison
CRMD
PRTC

About CRMD CorMedix Inc.

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: